Fig. 6: Individualized risk stratification by 24-gene expression score in LymphGen DNA subtypes.

All samples with available gene expression data and LymphGen DNA subtypes were combined for the analysis (n = 956). A Kaplan–Meier survival analysis showing the PFS in the individual LymphGen DNA subtypes. B Bar plots showing the distribution of high- and low-risk patients in the different DNA subtypes. C–J Kaplan–Meier survival analysis showing the PFS of high- and low-risk patients in the indicated DNA subtypes and the unclassified subtype. K Bar plots showing the distribution of high- and low-risk patients in the double-hits (n = 63) and double-expressors (n = 92) of MYC and BCL2. Among 1376 samples with 24-gene risk scores, 846 cases were evaluated for double-hit status, with 63 identified as double-hit. A total of 270 samples were assessed for double-expressor status, with 92 identified as double-expressors. Fisher’s exact test was used to compute p values. L, M Kaplan–Meier survival analysis showing the PFS of high- and low-risk patients in the indicated groups. UNC unclassified. For all Kaplan–Meier survival analyses, the p value was calculated by the log-rank test. Independent analyses in the discovery and validation cohorts are presented in Fig. S13.